(3R,6S)-6-(Hydroxymethyl)tetrahydro-2H-pyran-3-ol | 216099-02-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (3R,6S)-6-(Hydroxymethyl)tetrahydro-2H-pyran-3-ol
• 英文别名: (3R,6S)-6-(hydroxymethyl)oxan-3-ol
• CAS: 216099-02-4
• 化学式: C₆H₁₂O₃
• 分子量: 132.159
• InChiKey: SOCMOTOHJWIJEQ-RITPCOANSA-N

物化性质

• 沸点：
  275.0±20.0 °C(Predicted)
• 密度：
  1.168±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (3R,6S)-6-(Hydroxymethyl)tetrahydro-2H-pyran-3-ol 在 咪唑 、 4-二甲氨基吡啶 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 1,5-anhydro-3,4-dideoxy-6-O-[(1,1-dimethyl)ethyldimethyl]silyl-2-O-(methanesulfonyl)-D-erythro-hexitol
  参考文献：
  名称：

  Synthesis of Methylene-Expanded 2‘,3‘-Dideoxyribonucleosides

  摘要：

  A method for the preparation of methylene-expanded 2',3'-dideoxyribonucleosides is reported. The very inexpensive starting material levoglucosenone 8 was converted into the known mixture of alcohols 12ab which were converted into the required silyl ether alcohol 26 in six steps via either of two routes. The first involved a one-step acetylation and opening of the anhydro sugar bridge to give the triacetates 20ab which were reduced with triethylsilane and silyl triflate to afford the diacetates 21ab, both of which gave 26 after further functional group conversions. The second route entailed a simple acetylation of 12ab followed by reduction with triethylsilane and silyl triflate to give the monoacetates 19ab, both converted via straightforward chemistry into 26. Mesylation of the alcohol of 26 furnished the mesylate 27. Alkylation of adenine with the mesylate 27 afforded the silyl ether 28 which was deprotected to give the desired modified dideoxy nucleoside 7a. Alkylation of 2,6-diaminopurine 38 with the mesylate gave the protected diaminopurine nucleoside 39. Upon acetylation, it produced a mixture of di- and monoacetates 40-41, the latter of which was transformed into the desired guanosine analogue 7e. Thus, two new nucleoside analogues 7ae were prepared from levoglucosenone 8.

  DOI：

  10.1021/jo980436l
• 作为产物：
  描述：

  二氢左旋葡萄糖酮 在 三乙基硅烷 、 lithium aluminium tetrahydride 、 三氟甲磺酸三甲基硅酯 、 potassium carbonate 、 对甲苯磺酸 作用下， 以 甲醇 、 乙醚 、 乙腈 为溶剂， 反应 14.0h， 生成 (3R,6S)-6-(Hydroxymethyl)tetrahydro-2H-pyran-3-ol
  参考文献：
  名称：

  Synthesis of Methylene-Expanded 2‘,3‘-Dideoxyribonucleosides

  摘要：

  A method for the preparation of methylene-expanded 2',3'-dideoxyribonucleosides is reported. The very inexpensive starting material levoglucosenone 8 was converted into the known mixture of alcohols 12ab which were converted into the required silyl ether alcohol 26 in six steps via either of two routes. The first involved a one-step acetylation and opening of the anhydro sugar bridge to give the triacetates 20ab which were reduced with triethylsilane and silyl triflate to afford the diacetates 21ab, both of which gave 26 after further functional group conversions. The second route entailed a simple acetylation of 12ab followed by reduction with triethylsilane and silyl triflate to give the monoacetates 19ab, both converted via straightforward chemistry into 26. Mesylation of the alcohol of 26 furnished the mesylate 27. Alkylation of adenine with the mesylate 27 afforded the silyl ether 28 which was deprotected to give the desired modified dideoxy nucleoside 7a. Alkylation of 2,6-diaminopurine 38 with the mesylate gave the protected diaminopurine nucleoside 39. Upon acetylation, it produced a mixture of di- and monoacetates 40-41, the latter of which was transformed into the desired guanosine analogue 7e. Thus, two new nucleoside analogues 7ae were prepared from levoglucosenone 8.

  DOI：

  10.1021/jo980436l

文献信息

• Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
  申请人：Mayers L. George

  公开号：US20100062006A9

  公开（公告）日：2010-03-11

  The invention features compositions and methods for treating or alleviating a symptom of cancer. The compositions and methods of the invention direct supra-lethal doses of radiation, called Hot-Spots, to virtually all cancer cell types.

  该发明涉及用于治疗或缓解癌症症状的组合物和方法。该发明的组合物和方法将被称为“热点”的超致死剂量辐射直接照射到几乎所有癌细胞类型。
• US7615221B2
  申请人：——

  公开号：US7615221B2

  公开（公告）日：2009-11-10
• US7807136B2
  申请人：——

  公开号：US7807136B2

  公开（公告）日：2010-10-05
• [EN] PYRIMIDINE AND PYRIDINE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS<br/>[FR] DÉRIVÉS DE PYRIMIDINE ET DE PYRIDINE ET LEUR UTILISATION PHARMACEUTIQUE ET LEURS COMPOSITIONS
  申请人：PFIZER

  公开号：WO2009016498A1

  公开（公告）日：2009-02-05

  The prsent invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds as anti-inflammatory agents.
• [EN] ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF<br/>[FR] ANTICORPS ANTI-MSR1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：REGENERON PHARMA

  公开号：WO2019217591A1

  公开（公告）日：2019-11-14

  Provided herein are antibodies and antigen-binding fragments that bind MSR1 and methods of use thereof. According to certain embodiments, the antibodies bind human MSR1 with high affinity. In certain embodiments, the antibodies bind MSR1 without blocking, or blocking less than 90%, of modified LDL binding to MSR1. In some embodiments, the antibodies bind cell surface expressed-MSR1 and are internalized. The antibodies of the invention may be fully human antibodies. The invention includes anti-MSR1 antibodies, or antigen-binding fragments thereof, conjugated to drugs or therapeutic compounds.